Shifting Pharma from Profit to Patient by Delivering Scalable, Cost-Effective Treatments

Highlighting how decades of public distrust in pharma continue to challenge patient-centered missions
Exploring opportunities to rebuild trust through adherence programs, education, R&D, and rebalanced commercial focus
Case Study: Demonstrating innovation through a gene therapy case study for wet age-related macular degeneration
Ensuring manageable cost of goods and sound CMC strategy to scale patient access effectively
Delivering transformative, affordable therapies at scale to reinforce public health and rebuild trust